Catalyst Dossier · compiled by CeliA 🧫
Seagen Inc. (SGEN)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-12-15 (est.)Phase 2 · Tucatinib Oral Tabletimp 7/10
- 2026-12-31 (est.)Phase 2 · Sunitinibimp 7/10
- 2026-12-31 (est.)Phase 3 · brentuximab vedotinimp 9/10
- 2027-01-01 (est.)Phase 2 · Bleomycinimp 7/10
- 2027-01-01 (est.)Phase 2 · Enfortumab Vedotinimp 7/10
- 2027-01-29 (est.)Phase 3 · disitamab vedotinimp 9/10
- 2027-03-01 (est.)Phase 2 · tucatinibimp 7/10
- 2027-04-01 (est.)Phase 2 · Pertuzumabimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Adcetris | Approved | Hodgkin Lymphoma |
| Tukysa | Phase 2 | HER2+ Breast Cancer |
| SGN-40 | Phase 2 | Lymphoma, Large B-Cell, Diffuse |
| SGN-30 (monoclonal antibody) | Phase 2 | Hodgkin Disease |
| SGN-15 (cBR96-doxorubicin immunoconjugate) | Phase 2 | Prostatic Neoplasms |
| SGN-15 | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| SGN-30 (anti-CD30 mAb) | Phase 2 | Anaplastic Large-Cell Lymphoma |
| SEA-CD40 | Phase 2 | Melanoma |
| tucatinib | Phase 3 | Gastric Adenocarcinoma |
| Tisotumab Vedotin (HuMax-TF-ADC) | Phase 2 | Ovary Cancer |
| SGN-40 (anti-huCD40 mAb) | Phase 2 | Leukemia, Lymphocytic, Chronic |
| Lintuzumab (SGN-33) | Phase 2 | Acute Myeloid Leukemia |
| ladiratuzumab vedotin | Phase 2 | Triple Negative Breast Neoplasms |
| SGN-15, Docetaxel | Phase 2 | Non-Small Cell Lung Carcinoma |
| tisotumab vedotin | Phase 2 | Ovarian Cancer |
| SGN-30 | Phase 2 | Large Cell Lymphoma |
| brentuximab vedotin | Phase 3 | Lymphoma, B-Cell |
| Padcev | Phase 3 | Urothelial Cancer |
| sigvotatug vedotin | Phase 3 | Carcinoma, Non-Small-Cell Lung |
| disitamab vedotin | Phase 3 | Breast Neoplasms |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SGEN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.